Outcomes of patients with schizophrenia who discontinued long-acting injectable antipsychotic therapy due to adverse events: A chart review

• Main Authors: Hatano, M. (Author), Iwata, N. (Author), Kishi, T. (Author), Okuya, M. (Author), Sakuma, K. (Author)
• Format: Article
• Language: English
• Published: John Wiley and Sons Inc 2021
• Subjects: adult; adverse events; akathisia; Antipsychotic Agents; aripiprazole; Aripiprazole; Article; body weight gain; cholinergic receptor blocking agent; controlled study; delayed release formulation; Delayed-Action Preparations; drug withdrawal; extrapyramidal symptom; fatigue; female; health survey; hospitalization; human; Humans; hyperprolactinemia; injection site pain; long-acting injectable second-generation antipsychotic; major clinical study; male; medical record review; neuroleptic agent; paliperidone; Paliperidone Palmitate; psychopharmacotherapy; psychosis; rhabdomyolysis; risperidone; sample size; schizophrenia; Schizophrenia; side effect
• Online Access: View Fulltext in Publisher
• ISBN: 2574173X (ISSN)
• DOI: 10.1002/npr2.12192

Aim: We conducted a chart review to investigate the detailed outcomes of patients with schizophrenia who discontinued long-acting injectable second-generation antipsychotic (LAI-SGA) therapy due to adverse events (AEs). Methods: The study included patients with schizophrenia and related psychotic disorders who commenced LAI-SGA therapy between January/1//2009 and March/31/2020 at Fujita Health University Hospital in Toyoake, Japan. Results: We conducted a chart review of 157 patients with schizophrenia. At the time of this survey, 4 (6.9%), 5 (12.2%), and 10 (17.2%) of the patients in the aripiprazole once monthly, paliperidone palmitate, and risperidone-LAI groups, respectively, discontinued due to AEs since the start of LAI-SGA therapy. Three patients required hospitalization for AE treatment. Conclusion: The severity of these AEs in most patients is moderate (ie, no hospital treatment required). Due to the small sample size, a larger study is needed to confirm/replicate our study results. © 2021 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology